ImmunoGen Inc. (NASDAQ:IMGN) Signs Development And Commercialization Partnership For Mirvetuximab With Huadong Medicine For Greater China

ImmunoGen Inc. (NASDAQ:IMGN) has entered an exclusive collaboration with Huadong Medicine Co.’s wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceuticals Co. Ltd.

ImmunoGen to collaborate on the commercialization of mirvetuximab

The collaboration is for the development and commercialization of mirvetuximab soravtansine in Hong Kong, Taiwan, Macau, and mainland China. All rights for the development and commercialization of mirvetuximab in the rest of the globe will remain with ImmunoGen. The collaboration gives ImmunoGen access to the world’s second-largest pharmaceutical market. This is through the development, regulatory as well as commercial capabilities of Huadong Medicine. On the other hand, it supports the growth strategy of Huadong Medicine of building deep endocrinology, oncology, and autoimmunology drug portfolio. Mirvetuximab will add exciting late-stage cancer assets to the portfolio of Huadong Medicine.

Mark Enyedy, the CEO and President of ImmunoGen, said that Huadong Medicine has comprehensive regional experience; thus, it’s an ideal partner. Their development and regulatory capability, as well as access to a network of clinics and hospitals across Greater China, will be helpful. Enyedy said that collaboration reflects the potential of mirvetuximab in the treatment of ovarian cancer patients. The partnership also demonstrates the ability of immunoGen to translate its ADCs work into long-term relationships that create sustainable value for the company and its partners.

ImmunoGen to launch mirvetuximab in the US in 2022

Enyedy said that they are looking forward to the collaboration with Huadong Medicine in developing and commercializing mirvetuximab in Greater China. This is as the company advances the mirvetuximab program and also prepare for the first commercial launch in the US in 2022.

Huadong Medicine chairman Liang Lu said that ImmunoGen is a leader in ADCs development for treating cancer. Therefore, this partnership will bring a late-stage asset to Huadong Medicine, which will further enhance its pipeline of innovative oncology programs. Lu added that convincing clinical data so far generated demonstrates that mirvetuximab has the potential of becoming a promising therapy for a difficult to treat disease. He added that they are looking forward to commencing its development to meet the needs of ovarian cancer patients.